AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05549661
Drug: Onvansertib
RxNorm normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05562609
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampoules and packaging for all arms will be identical in appearance.
Trial: NCT05241873
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
Trial: NCT05241873
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
Trial: NCT05009329
Drug: JAB-21822
RxNorm normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAB-21822 will be administered orally
Trial: NCT06525077
Drug: FT218
RxNorm normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sodium oxybate for extended-release oral suspension
Trial: NCT04865887
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg, every 3 weeks, IV infusion
Trial: NCT04865887
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg (2 capsules x10mg), daily, orally
Trial: NCT06326411
Drug: NST-628
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
DrugBank: T-62 (DB12919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
Trial: NCT06519617
Drug: Yi Qi Yang Yin Decoction
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
Trial: NCT06519617
Drug: Hydroxychloroquine Sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
Trial: NCT06058585
Drug: Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone 10mg or 20mg tablets, oral, once daily
Trial: NCT06058585
Drug: Placebo Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone matched placebo tablets, oral, once daily
Trial: NCT06197217
Drug: WPV01
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Trial: NCT05661708
Drug: Chitosan
RxNorm normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
Trial: NCT05283408
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Trial: NCT05283408
Drug: Co-administration dexmedetomidine and low-dose esketamine infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Trial: NCT05283408
Drug: Co-administration dexmedetomidine and high-dose esketamine infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Trial: NCT05434234
Drug: YL201
RxNorm normalized name: Lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
Trial: NCT05245877
Drug: enoxaparin/tinzaparin/dalteparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
Trial: NCT05119140
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg of hydroxychloroquine per oral daily
Trial: NCT05119140
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
Trial: NCT05156268
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
Trial: NCT05156268
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib will be administered orally at 300 mg every 12 hours.
Trial: NCT06411860
Drug: Olpasiran
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a SC injection of olpasiran at dose level 1 or 2.
Trial: NCT06411860
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
Trial: NCT05323123
Drug: Pre-Exposure Prophylaxis (PrEP)
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved oral medication to reduce the risk of HIV infection
Trial: NCT05642325
Drug: Vamikibart
RxNorm normalized name: Vamikibart
DrugBank: Vamikibart (DB18896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive vamikibart IVT injection
Trial: NCT06100874
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
Trial: NCT06100874
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
Trial: NCT06100874
Drug: Trastuzumab and Hyaluronidase-oysk
RxNorm normalized name: TRASTUZUMAB/HYALURONIDASE-OYSK
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
Trial: NCT06544655
Drug: BMS-986484
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06544291
Drug: CBD 300mg
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
Trial: NCT06544291
Drug: CBD 600mg
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
Trial: NCT05155033
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
Trial: NCT05155033
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
Trial: NCT04855656
Drug: RP-6306
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PKMYT1 Inhibitor
Trial: NCT04855656
Drug: RP-3500
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ATR Inhibitor
Trial: NCT05879068
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04900792
Drug: Ferumoxytol injection
RxNorm normalized name: ferumoxytol Injection
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
Trial: NCT04900792
Drug: Pharmacological ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate
Trial: NCT04900792
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
Trial: NCT06202079
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec s.c., once-daily, treat-to-target dose
Trial: NCT06271330
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: switch from previous anti-VEGF agents to faricimab
Trial: NCT05864053
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine will be administered over a 45-minute period.
Trial: NCT05864053
Drug: (2R,6R)-hydroxynorketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
Trial: NCT05864053
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be administered over a 45-minute period.
Trial: NCT05687136
Drug: Tuvusertib
RxNorm normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06023043
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
Trial: NCT05335941
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT05335941
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT05335941
Drug: Etrumadenant
RxNorm normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05293717
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5% Ruxolitinib cream
Trial: NCT06531512
Drug: Xianglei Tangzu Gao
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Trial: NCT06532136
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 6 mg orally once daily.
Trial: NCT06216249
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
RxNorm normalized name: lutetium Lu 177 vipivotide tetraxetan
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05393024
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MMRR patients included in Named Patient Program e Expanded Access Program
Trial: NCT06410248
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06410248
Drug: Triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05222906
Drug: Venglustat
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet; oral
Trial: NCT05222906
Drug: imiglucerase
RxNorm normalized name: Imiglucerase
DrugBank: Imiglucerase (DB00053)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sterile lyophilized product; intravenous
Trial: NCT05534984
Drug: Tecovirimat Oral Capsule
RxNorm normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Trial: NCT05534984
Drug: Tecovirimat Oral Capsule (Open Label)
RxNorm normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Participants weighing 4 to \<6kg and \>7 days old - Tecovirimat 50mg every 12 hours for 14 days~* Participants weighing 2.5 to \<4kg and \>7 days to \<4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~* Participants weighing 4 to \<6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~* Participants weighing 2.5 to \<4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Trial: NCT04192773
Drug: IV Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
Trial: NCT06505759
Drug: Bromelain gel
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromelain gel is prepared from bromelain capsules in laboratory
Trial: NCT06505759
Drug: chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chlorhexidine gel is prepared from mouth wash
Trial: NCT04960579
Drug: Rimiducid
RxNorm normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety switch activator
Trial: NCT06444815
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-pd1 antibody
Trial: NCT05655949
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05655949
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05655949
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05903092
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500mg IV on Day 1 of every Cycle
Trial: NCT05903092
Drug: Monalizumab
RxNorm normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg IV on Day 1 of every Cycle
Trial: NCT05903092
Drug: Carboplatin or Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2
Trial: NCT05903092
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
Trial: NCT05908773
Drug: TTX-MC138-NODAGA-Cu64
RxNorm normalized name: TTX-MC138
DrugBank: TTX-MC138 (DB18628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
Trial: NCT05875493
Drug: JAB-21822
RxNorm normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 discrete single doses
Trial: NCT04731272
Drug: Dulaglutide 0.75Mg/0.5Ml Inj Pen
RxNorm normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
Trial: NCT04689048
Drug: 18F fluciclovine
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
Trial: NCT05986773
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
Trial: NCT05986773
Drug: Metolazone
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
Trial: NCT05986773
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).